Upadacitinib treatment in patients with moderate to severe atopic dermatitis: A retrospective single-centre Australian review of 14 patients post phase 3 clinical trial

被引：2
|
作者：
Bennett, Michaela [1 ,3 ]
Sinclair, Rodney D. [1 ,2 ]
Eisman, Samantha [1 ]
机构：
[1] Sinclair Dermatol, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Level 3,2 Wellington Parade, East Melbourne 3002, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷 / 01期
关键词：
atopic dermatitis; JAK; 1; inhibitors; JAK inhibitor treatment; Upadacitinib;
D O I：
10.1111/ajd.13969
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)-1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single-centre Australian cohort.
引用
收藏
页码：146 / 150
页数：5
相关论文
共 50 条
  • [1] Single-centre retrospective review of dupilumab-induced ocular surface disease in an Australian adult cohort with moderate-to-severe atopic dermatitis
    Arasu, Alexis
    Awad, Andrew
    Tran, Vanessa
    Ross, Gayle
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2025, 66 (01) : e24 - e27
  • [2] Treatment withdrawal and retreatment with upadacitinib in patients with moderate-to-severe atopic dermatitis from a phase IIb, randomized, controlled trial
    Reich, K.
    Thaci, D.
    Papp, K.
    Anderson, J.
    Hu, X.
    Gu, Y.
    Teixeira, H.
    Guttman-Yassky, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E98 - E99
  • [3] Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis
    Maurer, Marcus
    Cheung, Dorothy S.
    Theess, Wiebke
    Yang, Xiaoying
    Dolton, Michael
    Guttman, Anna
    Choy, David F.
    Dash, Ajit
    Grimbaldeston, Michele A.
    Soong, Weily
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 150 (06) : 1517 - 1524
  • [4] Upadacitinib for the management of severe alopecia areata in adolescent patients: a single-centre retrospective study
    Picone, Vincenzo
    Nappa, Paola
    Napolitano, Maddalena
    Vastarella, Maria
    Patruno, Cataldo
    Cantelli, Mariateresa
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024,
  • [5] Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy
    Chiricozzi, Andrea
    Costanzo, Antonio
    Levi, Anna
    Parretta, Federica
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2024, 11 : 38 - 50
  • [6] The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients
    Li, Lu
    Wu, Naming
    Liu, Tingyu
    Yu, Guoqun
    Wang, Yifei
    He, Ting
    Mao, Raymond
    Yang, Liu
    Li, Yan
    Shen, Chen
    Tao, Juan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 125
  • [7] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Beck, Lisa A.
    Anderson, Jaclyn K.
    Hu, Xiaofei
    Gu, Yihua
    Teixeira, Henrique D.
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB294 - AB294
  • [8] Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis
    Weidinger, Stephan
    Cork, Michael
    Reich, Adam
    Bieber, Thomas
    Gilbert, Sally
    Quaratino, Sonia
    Wilson, Rosamund
    Porter-Brown, Ben
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [9] Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis
    Weidinger, Stephan
    Cork, Michael
    Reich, Adam
    Bieber, Thomas
    Gilbert, Sally
    Quaratino, Sonia
    Wilson, Rosamund
    Porter-Brown, Ben
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB221 - AB221
  • [10] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Thaci, Diamant
    Papp, Kim A.
    Staender, Sonja
    Beck, Lisa A.
    Kim, Brian S.
    Hu, Xiaofei
    Liu, Jianzhong
    Calimlim, Brian M.
    Vigna, Namita
    Crowley, Jameson T.
    Teixeira, Henrique D.
    Thyssen, Jacob P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : 2558 - 2568
12345